Pharmaceuticals in U.S. health care: determinants of quantity and price.
暂无分享,去创建一个
[1] P. Nelson. Advertising as Information , 1974, Journal of Political Economy.
[2] R. Dorfman,et al. Optimal Advertising and Optimal Quality , 1976 .
[3] J. Newhouse. Free for All?: Lessons from the RAND Health Insurance Experiment , 1993 .
[4] P. Danzon,et al. Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU , 1997 .
[5] The Distribution and Pricing of Prescription Drugs , 1997 .
[6] J. Hellerstein,et al. The importance of the physician in the generic versus trade-name prescription decision. , 1998, The Rand journal of economics.
[7] W. S. Comanor,et al. Strategic Pricing of New Pharmaceuticals , 1998, Review of Economics and Statistics.
[8] E. Berndt,et al. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data. , 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] Michael Kremer,et al. Creating Markets for New Vaccines. Part I: Rationale , 2000, Innovation Policy and the Economy.
[10] Prescription Drugs: Continued Rapid Growth , 2000 .
[11] E. Berndt,et al. International comparisons of pharmaceutical prices: what do we know, and what does it mean? , 2000, Journal of health economics.
[12] M. Kremer. Creating Markets for New Vaccines. Part II: Design Issues , 2000, Innovation Policy and the Economy.
[13] P. Danzon,et al. Cross-national price differences for pharmaceuticals: how large, and why? , 2000, Journal of health economics.
[14] Christopher M. Snyder,et al. Countervailing Power in Wholesale Pharmaceuticals , 2001 .
[15] E. Berndt. The U.S. pharmaceutical industry: why major growth in times of cost containment? , 2001, Health affairs.
[16] R. Frank. Prescription drug prices: why do some pay more than others do? , 2001, Health affairs.
[17] F. Scherer,et al. The link between gross profitability and pharmaceutical R&D spending. , 2001, Health affairs.
[18] D. Petitti. Hormone replacement therapy for prevention: more evidence, more pessimism. , 2002, JAMA.
[19] S. Normand,et al. The Medical Treatment of Depression, 1991-1996: Productive Inefficiency, Expected Outcome Variations, and Price Indexes , 2000, Journal of health economics.
[20] J. DiMasi,et al. Returns on R&D for 1990s New Drug Introductions: Charts , 2003 .
[21] E. Berndt,et al. Promotion of prescription drugs to consumers. , 2002, The New England journal of medicine.
[22] Elliott S Fisher,et al. Geography and the debate over Medicare reform. , 2002, Health affairs.
[23] M. Kyle,et al. The Long Shadow of Patent Expiration , 2003 .
[24] M. Kyle,et al. The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches , 2003 .
[25] E. Berndt,et al. Demand Effects of Recent Changes in Prescription Drug Promotion , 2003 .